Commission on Commerce and Trade was held from Nov. 21st to 23th in Guangzhou, China. And it was presided jointly by Vice Premier of China State Council Mr. Wang Yang and the US Commerce Secretary Penny Pritzker. The Commission held a series of cooperative activities including China-US Entrepreneurs Roundtable, Economic and Trade cooperation meeting between US and China, Sanitary and Health Cooperation Seminar, etc.


It was on the morning of Nov.22nd that China-US Roundtable was held. 12 entrepreneurs from China and US were invited to attend the meeting to discuss about issues in terms of enterprise management and interaction between the government and enterprises. Chairman of the Board of Tasly Holding Group Mr. Yan Xijun was invited to attend the Roundtable and made a speech.

Chairman Yan Xijun expressed that it was the historical responsibility for Chinese pharmaceutical enterprises to promote TCM internationalization. As to Tasly, it has been communicating with American drug administration organizations during the 20 years since it had applied its TCM product Compound Danshen Dripping Pill (Dantonic Pill) of FAD certification in 1996.

Yan told that it was in 1996 that Tasly had initiated application of Dantonic Pill of certification to FDA and commenced the second application in 2006. In 2009, the Dantonic Pill had completed the phaseⅡof clinical research of FDA and has almost achieved the end of FDA Ⅲ clinical research during the experiment in 127 clinical research centers in 9 countries around the globe.

Chairman Yan said that we had found it was hard for TCM internationalization due to the difference in culture concept, thinking way, technological standard and regulations between the western and eastern. Form the point of view of enterprises, we can completely understand the difficult for TCM to enter into American market and make Americans accept TCM as well as the strictness towards drug administration of FDA for sake of American citizens' health.

However on the other hand, we had found FDA was positive towards TCM in face of the new challenge for approval of compound TCM application. After long terms' mutual communication, we had finally achieved a common view and worked out a consistent approach in terms of key complicated issues. And FDA had awarded Tasly with SPA (Special Protocol Assessment) and would approve Dantonic Pill to American market once it has completed the experiment according to the agreed clinical approach. The researches have been working well at present and we hope Dantonic Pill can get approval as the new drug to enter into American market in future under unprejudiced conditions.

distributed by